Search

Your search keyword '"Navashenaq, JG"' showing total 52 results

Search Constraints

Start Over You searched for: Author "Navashenaq, JG" Remove constraint Author: "Navashenaq, JG" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
52 results on '"Navashenaq, JG"'

Search Results

1. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019

2. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019

3. Current Nutritional Support in Critical Ill Covid-19 Patients: A Brief Review

4. Retraction notice to "Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models" [Life Sci. 288 (2022) 120166].

5. Dietary inflammatory index in relation to the progression of hepatic steatosis and liver fibrosis: evaluation by elastography/Fibroscan.

7. Correction to: association of the matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of coronavirus disease 2019 (COVID-19); implications of contribution for development of neurological symptoms in the COVID-19 patients.

8. Efferocytosis: a double-edged sword in microbial immunity.

10. Retraction Note: Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response.

11. Association of the matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of coronavirus disease 2019 (COVID-19); implications of contribution for development of neurological symptoms in the COVID-19 patients.

12. CRISPR: A Promising Tool for Cancer Therapy.

13. The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis.

14. Effect of diabetes on efferocytosis process.

15. Are levels of adipokines and micronutrients different in male adult smokers and non-smokers? A case-control study.

16. The relationship between major dietary patterns and disease activity of rheumatoid arthritis.

17. Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.

18. Xanthohumol: An underestimated, while potent and promising chemotherapeutic agent in cancer treatment.

19. The effect of Vitamin C and Zn supplementation on the immune system and clinical outcomes in COVID-19 patients.

20. Identification of G-quadruplex anti-Interleukin-2 aptamer with high specificity through SELEX stringency.

21. Probiotic supplementation: A prospective approach in the treatment of COVID-19.

22. Effects of microwave technology on the subcutaneous abdominal fat and anthropometric indices of overweight adults: A clinical trial.

23. Berberine as a natural modulator of inflammatory signaling pathways in the immune system: Focus on NF-κB, JAK/STAT, and MAPK signaling pathways.

24. The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes for Orthopedic Diseases Treatment.

25. The role of efferocytosis in neuro-degenerative diseases.

26. Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response.

27. Curcumin as a Natural Modulator of B Lymphocytes: Evidence from In Vitro and In Vivo Studies.

28. MicroRNAs and Efferocytosis: Implications for Diagnosis and Therapy.

29. Antennapedia-derived positively-charged peptide faces multiple problems upon their usage as targeting ligand for liposomal doxorubicin.

30. Arctigenin, an anti-tumor agent; a cutting-edge topic and up-to-the-minute approach in cancer treatment.

31. The effect of RGD-targeted and non-targeted liposomal Galbanic acid on the therapeutic efficacy of pegylated liposomal doxorubicin: From liposomal preparation to in-vivo studies.

32. Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients.

33. Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2.

34. The role of non-coding genome in the behavior of infiltrated myeloid-derived suppressor cells in tumor microenvironment; a perspective and state-of-the-art in cancer targeted therapy.

35. Nigella sativa in controlling Type 2 diabetes, cardiovascular, and rheumatoid arthritis diseases: Molecular aspects.

36. The role of myeloid-derived suppressor cells in rheumatoid arthritis: An update.

37. A comprehensive review of long non-coding RNAs in the pathogenesis and development of non-alcoholic fatty liver disease.

38. Postprandial effects of macronutrient composition meals on the metabolic responses and arterial stiffness indices of lean and obese male adults: a protocol of a pilot study.

39. A systematic review of preclinical studies on the efficacy of propolis for the treatment of inflammatory bowel disease.

40. The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy.

41. Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials.

42. Molecular and cellular mechanisms of the effects of Propolis in inflammation, oxidative stress and glycemic control in chronic diseases.

43. Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy.

44. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.

45. Doxil chemotherapy plus liposomal P5 immunotherapy decreased myeloid-derived suppressor cells in murine model of breast cancer.

46. MicroRNAs as important regulators of the NLRP3 inflammasome.

47. Targeted-nanoliposomal combretastatin A4 (CA-4) as an efficient antivascular candidate in the metastatic cancer treatment.

48. The therapeutic and diagnostic role of exosomes in cardiovascular diseases.

49. Possible molecular mechanisms of glucose-lowering activities of Momordica charantia (karela) in diabetes.

50. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.

Catalog

Books, media, physical & digital resources